|Videos|July 13, 2016

How Are Superbugs Transferred Between People?

Prof. Andrea Endimiani, MD, PhD, from the Institute of Infectious Diseases at the University of Bern, Switzerland, explains the method by which bacteria carrying the mcr-1 gene are transmitted between people.

Prof. Andrea Endimiani, MD, PhD, from the Institute of Infectious Diseases at the University of Bern, Switzerland, explains the method by which bacteria carrying the mcr-1 gene are transmitted between people.

Interview Transcript (slightly modified for readability)

“The transmission of bacteria carrying mcr-1 between humans follows the same rules of [the transmission of] other pathogens, like those that produce [Extended Spectrum Beta-Lactamase (ESBL)] or Carbopenemases. If we are in a hospital, and we have a patient [who] is infected or colonized at [the] intestinal level, and is in contact with the [hospital] personnel or directly with other patients, [then the patient] can transmit [the gene] via, for example, the hands. We know very well that we have to wash [our] hands, use gloves, [and so on], to stop the transmission of the bacteria between humans.

It is not important if the original patient with mcr-1 is infected, [the patient] can be only a carrier at [the] intestinal level and can [still] transmit [the gene] to another person [who] can [then either] be infected or colonized. The difference is substantial but epidemiologically not very relevant. In hospitals in western countries, we have many patients [who are] only colonized at [the] intestinal level with superbugs. We have to be very careful when we approach these patients; for example, [we can] put them in isolation to prevent [bacterial] transmission to other patients [who] are not yet colonized.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.